These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 27507852)

  • 1. FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model.
    Gstalder C; Ader I; Cuvillier O
    Mol Cancer Ther; 2016 Oct; 15(10):2465-2474. PubMed ID: 27507852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer.
    Ader I; Gstalder C; Bouquerel P; Golzio M; Andrieu G; Zalvidea S; Richard S; Sabbadini RA; Malavaud B; Cuvillier O
    Oncotarget; 2015 May; 6(15):13803-21. PubMed ID: 25915662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel role of sphingosine kinase-1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma.
    Salama MF; Carroll B; Adada M; Pulkoski-Gross M; Hannun YA; Obeid LM
    FASEB J; 2015 Jul; 29(7):2803-13. PubMed ID: 25805832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pimitespib, a Novel Heat Shock Protein 90 Inhibitor, Is Effective in Treating Renal Cell Carcinoma by Anti-angiogenetic Signaling.
    Teranishi R; Takahashi T; Kurokawa Y; Saito T; Yamamoto K; Momose K; Yamashita K; Tanaka K; Makino T; Nakajima K; Eguchi H; Doki Y
    Anticancer Res; 2024 Aug; 44(8):3343-3348. PubMed ID: 39060043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
    Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
    Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.
    Horiguchi A; Asano T; Kuroda K; Sato A; Asakuma J; Ito K; Hayakawa M; Sumitomo M; Asano T
    Br J Cancer; 2010 May; 102(11):1592-9. PubMed ID: 20461084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway.
    Beider K; Rosenberg E; Bitner H; Shimoni A; Leiba M; Koren-Michowitz M; Ribakovsky E; Klein S; Olam D; Weiss L; Wald H; Abraham M; Galun E; Peled A; Nagler A
    Clin Cancer Res; 2017 Apr; 23(7):1733-1747. PubMed ID: 27697999
    [No Abstract]   [Full Text] [Related]  

  • 8. FTY720 enhances TRAIL-mediated apoptosis by up-regulating DR5 and down-regulating Mcl-1 in cancer cells.
    Woo SM; Seo BR; Min KJ; Kwon TK
    Oncotarget; 2015 May; 6(13):11614-26. PubMed ID: 25843953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
    Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
    Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.
    Li W; Li J; Wang Y; Zhang K; Li N; Tian Z; Ni B; Wang H; Ruan Z
    Oncotarget; 2016 Dec; 7(49):80586-80598. PubMed ID: 27811359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPHK1 Is a Novel Target of Metformin in Ovarian Cancer.
    Hart PC; Chiyoda T; Liu X; Weigert M; Curtis M; Chiang CY; Loth R; Lastra R; McGregor SM; Locasale JW; Lengyel E; Romero IL
    Mol Cancer Res; 2019 Apr; 17(4):870-881. PubMed ID: 30655321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.
    McCracken AN; McMonigle RJ; Tessier J; Fransson R; Perryman MS; Chen B; Keebaugh A; Selwan E; Barr SA; Kim SM; Roy SG; Liu G; Fallegger D; Sernissi L; Brandt C; Moitessier N; Snider AJ; Clare S; Müschen M; Huwiler A; Kleinman MT; Hanessian S; Edinger AL
    Leukemia; 2017 Mar; 31(3):669-677. PubMed ID: 27573555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma.
    Qiu B; Ackerman D; Sanchez DJ; Li B; Ochocki JD; Grazioli A; Bobrovnikova-Marjon E; Diehl JA; Keith B; Simon MC
    Cancer Discov; 2015 Jun; 5(6):652-67. PubMed ID: 25829424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
    Butler J; Lana D; Round O; LaMontagne K
    Prostaglandins Other Lipid Mediat; 2004 Jan; 73(1-2):29-45. PubMed ID: 15165029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis.
    Joshi S; Singh AR; Zulcic M; Durden DL
    Mol Cancer Res; 2014 Oct; 12(10):1520-31. PubMed ID: 25103499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer.
    Katsuta E; Yan L; Nagahashi M; Raza A; Sturgill JL; Lyon DE; Rashid OM; Hait NC; Takabe K
    J Surg Res; 2017 Nov; 219():202-213. PubMed ID: 29078883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of HIF1α in renal cell carcinoma tumorigenesis.
    Gudas LJ; Fu L; Minton DR; Mongan NP; Nanus DM
    J Mol Med (Berl); 2014 Aug; 92(8):825-36. PubMed ID: 24916472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the SphK1/S1P/S1PR1 Axis That Links Obesity, Chronic Inflammation, and Breast Cancer Metastasis.
    Nagahashi M; Yamada A; Katsuta E; Aoyagi T; Huang WC; Terracina KP; Hait NC; Allegood JC; Tsuchida J; Yuza K; Nakajima M; Abe M; Sakimura K; Milstien S; Wakai T; Spiegel S; Takabe K
    Cancer Res; 2018 Apr; 78(7):1713-1725. PubMed ID: 29351902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targets of FTY720 (fingolimod).
    Pitman MR; Woodcock JM; Lopez AF; Pitson SM
    Curr Mol Med; 2012 Dec; 12(10):1207-19. PubMed ID: 22834825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma.
    Wong SC; Cheng W; Hamilton H; Nicholas AL; Wakefield DH; Almeida A; Blokhin AV; Carlson J; Neal ZC; Subbotin V; Zhang G; Hegge J; Bertin S; Trubetskoy VS; Rozema DB; Lewis DL; Kanner SB
    Mol Cancer Ther; 2018 Jan; 17(1):140-149. PubMed ID: 29079709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.